See the DrugPatentWatch profile for mounjaro
Eli Lilly holds multiple patents related to tirzepatide, the active ingredient in Mounjaro [1]. These patents cover various aspects of the drug, including its composition of matter, methods of use, and manufacturing processes [1]. DrugPatentWatch.com tracks these patents and their expiration dates [2].
When does Mounjaro's main patent expire?
The primary patents protecting tirzepatide are expected to expire around 2037 [1]. However, the exact expiration dates can vary due to different patent filings and potential extensions [1][2].
Are there other patents protecting Mounjaro?
In addition to composition of matter patents, Eli Lilly has obtained patents on specific formulations, methods of treatment, and manufacturing techniques for tirzepatide [1]. These secondary patents could extend market exclusivity for Mounjaro beyond the expiration of the initial composition of matter patents [2].
Can generic versions of Mounjaro be made before patents expire?
Generic manufacturers typically must wait for all relevant patents to expire before they can legally market a biosimilar or generic version of a drug [3]. If a generic company challenges a patent and is successful, or if the patent expires, they may be able to launch their product earlier [2][3]. However, patent litigation can be complex and lengthy [2].
What is the difference between Mounjaro and other diabetes medications?
Mounjaro (tirzepatide) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist [4]. This dual mechanism of action differentiates it from other diabetes medications, such as GLP-1 receptor agonists (like semaglutide) or DPP-4 inhibitors [4]. Tirzepatide has demonstrated significant efficacy in improving glycemic control and promoting weight loss in clinical trials [4][5].
How does Mounjaro compare to other GLP-1 drugs?
Tirzepatide, the active ingredient in Mounjaro, acts on both GIP and GLP-1 receptors, whereas many other diabetes drugs in this class, like semaglutide (Ozempic, Wegovy), primarily target GLP-1 receptors [4][6]. Clinical studies have shown tirzepatide to be more effective in reducing A1C levels and body weight compared to selective GLP-1 receptor agonists [5].
What are the clinical trial results for Mounjaro?
Clinical trials for tirzepatide have shown substantial reductions in HbA1c levels and body weight for individuals with type 2 diabetes [4][5]. For instance, the SURMOUNT-1 trial demonstrated significant weight loss in adults with obesity or overweight and at least one weight-related comorbidity, without diabetes [5].
What are the side effects of Mounjaro?
Common side effects associated with Mounjaro include gastrointestinal issues such as nausea, vomiting, diarrhea, decreased appetite, and abdominal pain [4]. More serious side effects can occur, and patients are advised to discuss potential risks with their healthcare provider [4].
What is the regulatory status of Mounjaro?
Mounjaro is approved by the U.S. Food and Drug Administration (FDA) for the treatment of type 2 diabetes [4]. It has also received approval for chronic weight management in individuals with obesity or overweight and at least one weight-related condition [5].
Who manufactures Mounjaro?
Mounjaro is manufactured by Eli Lilly and Company [4].
Sources
1. DrugPatentWatch.com. (n.d.). Tirzepatide patents. Retrieved from https://www.drugpatentwatch.com/
2. DrugPatentWatch.com. (n.d.). Eli Lilly drug patents. Retrieved from https://www.drugpatentwatch.com/
3. U.S. Food & Drug Administration. (2020). Generic Drugs: Questions & Answers. Retrieved from https://www.fda.gov/drugs/generic-drugs/generic-drugs-questions-answers
4. Mounjaro® Prescribing Information. (n.d.). Eli Lilly and Company.
5. Jastreboff, A. M., et al. (2022). Tirzepatide once weekly for the treatment of adults with obesity. The New England Journal of Medicine, 387(3), 205-216.
6. DrugPatentWatch.com. (n.d.). Semaglutide patents. Retrieved from https://www.drugpatentwatch.com/